Moderna participated in the U.S. FDA’s Vaccines and Related Biological Products Advisory Committee meeting on May 28, 2026. The panel voted to recommend the specific strain for 2026-2027 COVID-19 vaccine boosters. Moderna confirmed readiness to manufacture and supply the updated vaccine composition by mid-August, pending regulatory approval.
On the same day, Moderna presented at Bernstein’s 42nd Annual Strategic Decisions Conference. The company detailed its strategic evolution from a research-focused entity to a global commercial operation. Key discussion points included a diversified vaccine and oncology pipeline and disciplined cost management. Moderna is integrating AI and digital technologies to accelerate innovation and operational efficiency.